Proscia announces new study data on artificial intelligence’s ability to detect melanoma.
The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma.
Case-based observations offered clinicians real-world guidance on distinguishing underlying malignancies in the Therapeutic Hotline session at Maui Derm NP+PA Fall 2021.
Coppertone has issued a voluntary recall for 12 lots of its aerosol sunscreen, citing detected levels of the carcinogen benzene.
As a part of her Maui Derm NP+PA Fall 2021 presentation, Phoebe Rich, MD, discusses how different diseases manifest in the nails, including multiple patient examples, and whether or not biopsy is needed for diagnosis.
The EADV congress today presents new study data showing that skin cancer detection apps fail to correctly categorize rare and aggressive cancers as high-risk.
Possible melanoma treatments have had multiple newsworthy events since July 2021.
Bristol Myers Squibb has announced that the FDA has accepted the Biologics License Application (BLA) for relatlimab and nivolumab, a fixed-dose combination treatment for unresectable or metastatic melanoma.
DermTech’s Pigmented Lesion Assay data was published in SKIN: The Journal of Cutaneous Medicine showing the results of its melanoma detection.